臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

???ui.leftmenu.abouttair???
	???ui.leftmenu.explanation???

???ui.leftmenu.bartitle???
	Repositories
	Author
	Title
	Date
	???ui.leftmenu.statisticschart???
	???ui.leftmenu.realtimefacts???
	???ui.leftmenu.trend???

???index.news???
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

???ui.leftmenu.copyrighttitle???
	???ui.leftmenu.copyrightpublisher???
	???ui.leftmenu.copyrightconference???

???ui.leftmenu.link???
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"pei jer chen"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1???	???jsp.browse.items-by-author.order2???

Showing items 651-675 of 883 (36 Page(s) Totally)
<< < 22 23 24 25 26 27 28 29 30 31 > >>
View [10|25|50] records per page

Institution	Date	Title	Author
臺大學術典藏	2021-07-03T03:33:27Z	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy	Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-07-03T03:33:27Z	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan	Liu C.-H.; Liu C.-J.; Hung C.-C.; Hsieh S.-M.; Su T.-H.; Sun H.-Y.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-07-03T03:33:26Z	HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis	Tseng T.-C.; Liu C.-J.; Chang C.T.; Su T.-H.; Yang W.-T.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-07-03T03:33:26Z	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment	Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; Liu C.-J.; Su T.-H.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-07-03T03:33:26Z	HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice	Horng J.-H.; Lin W.-H.; Wu C.-R.; Lin Y.-Y.; Wu L.-L.; Chen D.-S.; PEI-JER CHEN
臺大學術典藏	2021-07-03T03:33:26Z	Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals	Liu C.-H.; Lee M.-H.; Lin J.-W.; Liu C.-J.; Su T.-H.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-07-03T03:33:25Z	Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19)	Chang F.-Y.; Chen H.-C.; PEI-JER CHEN; Ho M.-S.; Hsieh S.-L.; Lin J.-C.; Liu F.-T.; Sytwu H.-K.
臺大學術典藏	2021-07-03T03:33:25Z	Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection	Cheng X.; Uchida T.; Xia Y.; Umarova R.; Liu C.-J.; PEI-JER CHEN; Gaggar A.; Suri V.; M?cke M.M.; Vermehren J.; Zeuzem S.; Teraoka Y.; Osawa M.; Aikata H.; Tsuji K.; Mori N.; Hige S.; Karino Y.; Imamura M.; Chayama K.; Liang T.J.
臺大學術典藏	2021-07-03T03:33:25Z	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population	Yu M.-L.; PEI-JER CHEN; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L.
臺大學術典藏	2021-07-03T03:33:24Z	Performance of commercially available anti-HDV enzyme-linked immunosorbent assays in Taiwan	Lin G.-Y.; Wu Y.-L.; Wang C.-S.; Ko C.-Y.; Chen C.-H.; PEI-JER CHEN; Peng P.-H.; Hsu C.-W.
臺大學術典藏	2021-07-03T03:33:24Z	The origin and underlying driving forces of the SARS-CoV-2 outbreak	Chaw S.-M.; Tai J.-H.; Chen S.-L.; Hsieh C.-H.; Chang S.-Y.; Yeh S.-H.; Yang W.-S.; PEI-JER CHEN; Wang H.-Y.
臺大學術典藏	2021-07-03T03:33:24Z	Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing	Yang Y.-C.; Chen Y.-H.; Kao J.-H.; Ching C.; Liu I.-J.; Wang C.-C.; Tsai C.-H.; Wu F.-Y.; Liu C.-J.; PEI-JER CHEN; Chen D.-S.; Yang H.-C.
臺大學術典藏	2021-07-03T03:33:23Z	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data	Hong C.-M.; Liu C.-H.; Su T.-H.; Yang H.-C.; PEI-JER CHEN; Chen Y.-W.; Kao J.-H.; Liu C.-J.
臺大學術典藏	2021-07-03T03:33:23Z	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations	Yu M.-L.; PEI-JER CHEN; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L.
臺大學術典藏	2021-07-03T03:33:23Z	The role of phylogenetic analysis in clarifying the infection source of a COVID-19 patient	Wang J.-T.; Lin Y.-Y.; Chang S.-Y.; Yeh S.-H.; Hu B.-H.; PEI-JER CHEN; Chang S.-C.
臺大學術典藏	2021-07-03T03:33:23Z	Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer	Su T.-H.; Tseng T.-C.; Liu C.-J.; Chou S.-W.; Liu C.-H.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Chen C.-L.; Kao J.-H.
臺大學術典藏	2021-07-03T03:33:22Z	Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials	Asahina Y.; Liu C.-J.; Gane E.; Itoh Y.; Kawada N.; Ueno Y.; Youn J.; Wang C.-Y.; Llewellyn J.; Matsuda T.; Gaggar A.; Mo H.; Dvory-Sobol H.; Crans G.; Chuang W.-L.; PEI-JER CHEN; Enomoto N.
臺大學術典藏	2021-07-03T03:33:22Z	Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan	Su H.-J.; Kao J.-H.; Tseng T.-C.; Yang H.-C.; Su T.-H.; PEI-JER CHEN; Liu C.-J.
臺大學術典藏	2021-07-03T03:33:22Z	Disease burden from foodborne illnesses in Taiwan, 2012–2015	Lai Y.-H.; Chung Y.-A.; Wu Y.-C.; Fang C.-T.; PEI-JER CHEN
臺大學術典藏	2021-07-03T03:33:22Z	Elimination of hepatitis B in highly endemic settings: Lessons learned in Taiwan and challenges ahead	Liu C.-J.; PEI-JER CHEN
臺大學術典藏	2021-07-03T03:33:21Z	High risk of clinical relapse in patients with chronic Hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy	Chang W.-Y.; Chiu Y.-C.; Chiu F.-W.; Hsu Y.-C.; Tseng T.-C.; Cheng P.-N.; Yang S.-S.; Liu C.-J.; Su T.-H.; Yang H.-C.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-07-03T03:33:21Z	Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects	Cheng Y.-W.; Chao T.-L.; Li C.-L.; Chiu M.-F.; Kao H.-C.; Wang S.-H.; Pang Y.-H.; Lin C.-H.; Tsai Y.-M.; Lee W.-H.; Tao M.-H.; Ho T.-C.; Wu P.-Y.; Jang L.-T.; PEI-JER CHEN; Chang S.-Y.; Yeh S.-H.
臺大學術典藏	2021-07-03T03:33:20Z	Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinoma	Huang B.-Y.; Tsai M.-R.; Hsu J.-K.; Lin C.-Y.; Lin C.-L.; Hu J.-T.; Huang Y.-W.; Liu C.-J.; Wu W.-J.; Wu C.-F.; Sung F.-Y.; PEI-JER CHEN; Liang H.-J.; Lin S.-M.; Yu M.-W.
臺大學術典藏	2021-07-03T03:33:20Z	Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan	Liu C.-H.; Su T.-H.; Liu C.-J.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-07-03T03:33:20Z	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis	Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.

Showing items 651-675 of 883 (36 Page(s) Totally)
<< < 22 23 24 25 26 27 28 29 30 31 > >>
View [10|25|50] records per page

	English \| 正體中文 \| 简体中文 \| 2822924
	???header.visitor??? : 30011603 ???header.onlineuser??? : 1025 ???header.sponsordeclaration???